A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer

Outpatient Oncology Unit, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Cancer Chemotherapy and Pharmacology (Impact Factor: 2.77). 07/2011; 68(1):157-64. DOI: 10.1007/s00280-010-1470-2
Source: PubMed


Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy.
Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy. The primary endpoint was safety for phase I and feasibility of oral curcumin for phase II study.
Twenty-one patients were enrolled. No dose-limiting toxicities were observed in the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the phase II study. No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79-100%). Median survival time after initiation of curcumin was 161 days (95% confidence interval 109-223 days) and 1-year survival rate was 19% (4.4-41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients tested.
Combination therapy using 8 g oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer and warrants further investigation into its efficacy.

Download full-text


Available from: Masashi Kanai,
  • Source
    • "Henceforth combining them synergistically with synthetic chemotherapeutic drugs would yield a dependable therapeutic tool for circumventing cancer. Curcumin has augmented anticancer activity of gemcitabine and 5FU [26] [27] while resveratrol has sensitized human cancer cell lines such as neuroblastoma, glioblastoma , and breast carcinoma, prostate carcinoma to chemotherapeutic agents such as doxorubicin, cytarabine, taxol, and methotrexate [28]. Another flavonoid, myricetin in combination of with 5-fluorouracil was found to increase tumor chemosensitivity of esophageal cancer cells [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An insight into the complex cancer pathophysiology reveals that a dependable amelioration of the disease could only be envisaged with a multipronged treatment approach. It is highly evident that singular chemotherapeutic agents used in clinical practice have shown limitations like severe side effects, MDR and are often associated with poor QOL while combinations of drugs have yielded better therapeutic outcomes. The current hypothesis takes it a step forward wherein a chemotherapeutic agent is combined with a natural chemosensitizer, both loaded into a nanopotentiated particulate system, which would eventually deliver the drug cargo at the target site with certitude. The encapsulated natural bioactive would then favorably act on the tumor milieu through multiple portals and chemosensibilize the cells towards cytotoxic action of the synthetic drug moiety. This 2C (chemotherapeutic and chemosensitizer) approach along with nanosystem's attributes like high payload, prolonged action and diminished side effects would proffer a more dependable treatment modality. In conclusion, the proposed system would be a value addition to the currently available armamentarium of cancer treatment tools. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Medical Hypotheses 03/2015; 84(6). DOI:10.1016/j.mehy.2015.03.003 · 1.07 Impact Factor
  • Source
    • "It was found that curcumin treatment led to a reduction in IKKβ kinase activity in the salivary cells of head and neck squamous cell carcinoma [155]. A study was performed to evaluate the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy on twenty-one patients and showed 8 gms oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer [156]. Another important study was performed on patients with colorectal cancer and patients were ingested curcumin capsules with a dose of (3.6 g, 1.8 and 4.5 g daily) for 7 days. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is the most dreadful disease worldwide in terms of morbidity and mortality. The exact cause of cancer development and progression is not fully known. But it is thought that cancer occurs due to the structural and functional changes in the genes. The current approach to cancer treatment based on allopathic is expensive, exhibits side effects; and may also alter the normal functioning of genes. Thus, a safe and effective mode of treatment is needed to control the cancer development and progression. Some medicinal plants provide a safe, effective and affordable remedy to control the progression of malignant cells. The importance of medicinal plants and their constituents has been documented in Ayurveda, Unani medicine, and various religious books. Curcumin, a vital constituent of the spice turmeric, is an alternative approach in the prevention of cancer. Earlier studies have shown the effect of curcumin as an antioxidant, antibacterial, antitumor and it also has a noteworthy role in the control of different diseases. In this review, we summarize the understanding of chemopreventive effects of curcumin in the prevention of cancer via the regulation of various cell signaling and genetic pathways.
    BioMed Research International 09/2014; 2014:761608. DOI:10.1155/2014/761608 · 2.71 Impact Factor
    • "Pharmacokinetics parameters of curcumin were measured in patients after the consumption of 8 g of curcumin. No toxicity was observed in patients with curcumin ingestion.[3536] Curcumin plasma level range was from 29 to 419 ng/mL,[36] and 22 to 42 ng/mL after 2–6 hours after single dose.[35] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: 131-radioiodine has been widely used as an effective radionuclide for treatment of patients with thyroid diseases. The purpose of the present study is to investigate the radioprotective effects of curcumin as a natural product that protects against the genotoxic effects of 131I in human cultured lymphocytes. Materials and Methods: Whole blood samples from human volunteers were incubated with curcumin at doses of 5, 10, and 50 μg/mL. After 1-hour incubation, the lymphocytes were incubated with 131I (100 μCi/1.5 ml) for 2 hours. The lymphocyte cultures were then mitogenically stimulated to allow for evaluation of the number of micronuclei in cytokinesis-blocked binucleated cells. Results: Incubation of lymphocytes with 131I at dose 100 μCi/1.5 mL induced genotoxicity shown by increase in micronuclei frequency in human lymphocytes. Curcumin at 5, 10, and 50 μg/mL doses significantly reduced the micronuclei frequency. Maximal protective effects and greatest decrease in micronuclei frequency were observed when whole blood was incubated with 50 μg/mL dose of curcumin with 52%. Conclusion: This study has important implications for patients undergoing 131I therapy. Our results indicate a protective role for curcumin against the genetic damage and side effects induced by 131I administration.
    Pharmacognosy Magazine 04/2014; 10(38):106-10. DOI:10.4103/0973-1296.131020 · 1.26 Impact Factor
Show more